DK2299953T3 - Bærestofsammensætning til lægemidler med vedvarende udløsning - Google Patents
Bærestofsammensætning til lægemidler med vedvarende udløsning Download PDFInfo
- Publication number
- DK2299953T3 DK2299953T3 DK09797631.0T DK09797631T DK2299953T3 DK 2299953 T3 DK2299953 T3 DK 2299953T3 DK 09797631 T DK09797631 T DK 09797631T DK 2299953 T3 DK2299953 T3 DK 2299953T3
- Authority
- DK
- Denmark
- Prior art keywords
- another embodiment
- bone
- lipid
- fatty acid
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/22—Lipids, fatty acids, e.g. prostaglandins, oils, fats, waxes
- A61L2300/222—Steroids, e.g. corticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/406—Antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/80—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form
- A61L2300/802—Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/04—Coatings containing a composite material such as inorganic/organic, i.e. material comprising different phases
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Polymers & Plastics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (14)
- BÆRESTOFSAMMENSÆTNING TIL LÆGEMIDLER MED VEDVARENDE UDLØSNING Patentkrav (reproklart materiale)1. Substrat, hvis overflade er helt eller delvis coatet med en biokompatibel matrixsammensætning, hvilken matrixsammensætning omfatter: a) en biologisk nedbrydelig polyester, der er ikke-kovalentknyttet til en første lipid, som omfatter en sterol; b) en anden lipid omfattende mindst én phosphatidylcholin med fédtsyredele på mindst 14 carbonatomer; c) et farmaceutisk aktivt middel; hvori matrixsammensætningen er lipidmættet, vægtforholdet mellem lipider i alt og den biologisk nedbrydelige polyester er mellem fra og med 1,5:1 og til og med 9:1, sterolen udgør op til 40 molprocent af matrixens samlede lipidindhold og, når den holdes i et vandigt miljø, tilvejebringer vedvarende udløsning af det farmaceutisk aktive middel.
- 2. Coatet substrat ifølge krav 1, hvori mindst ét af følgende er sandt: (a) substratet omfatter mindst ét materiale udvalgt fra gruppen bestående af hydroxyapatit, rustfrit stål, cobalt-chrom, titaniumlegering, tantalum, keramik og gelatine; (b) substratet er udvalgt fra ortopædiske søm, ortopædiske skruer, ortopædiske stapler, ortopædiske tråde, ortopædiske stifter, metal- eller polymerimplantater, knoglefyldningspartikler, kollagen- og ikke-kollagenmembraner, suturmaterialer, ortopædiske cementer og svampe, fortrinsvis hvori knoglefyldningspartiklerne er udvalgt fra allogene, xenogene og kunstige knoglepartikler.
- 3. Coatet substrat ifølge et hvilket som helst af kravene 1 eller 2, hvori mindst ét af følgende er sandt: (a) den biologisk nedbrydelige polyester er udvalgt fra gruppen bestående af PLA (polymælkesyre), PGA (polyglycolsyre) og PLGA (poly-(mælke-co-glycolsyre); (b) sterolen er en kolesterol; (c) matrixsammensætningen omfatter en flerhed af farmaceutisk aktive midler udvalgt fra et antibiotikum, et antimykotikum, et non-steroidt antiinflammatorisk lægemiddel (NSAID), et steroid, et anticancermiddel, en osteogen faktor og en knogleresorptionshæmmer; (d) matrixsammensætningen er homogen; (e) matrixsammensætningen omfatter en sphingolipid; (f) matrixsammensætningen omfatter en tocopherol; (g) matrixsammensætningen omfatter endvidere en yderligere phospholipid udvalgt Ira gruppen bestående af phosphatidylserin, en phosphatidylglycerol og en pho sphatidylino sitol; (h) matrixsammensætningen omfatter endvidere en fri fedtsyre på 14 eller flere carbonatomer; (i) matrixsammensætningen omfatter endvidere en målretningsdel, der er i stand til at interagere med et målmolekyle udvalgt fra gruppen bestående af et kollagenmolekyle, et fibrinmolekyle og en heparin, fortrinsvis hvori målretningsdelen er et fibronectinpeptid; (j) matrixsammensætningen omfatter endvidere en PEGyleret lipid.
- 4. Coatet substrat ifølge et hvilket som helst af kravene 1 til 3, hvori det farmaceutisk aktive middel er udvalgt fra et antibiotikum, et antimykotikum, et non-steroidt antiinflammatorisk lægemiddel, et steroid, et anticancermiddel, en osteogen faktor og en knogleresorptionshæmmer.
- 5. Coatet substrat ifølge krav 4, hvori det farmaceutisk aktive middel er udvalgt fra et antibiotikum eller et antimykotikum; eller hvori det farmaceutisk aktive middel er et non-steroidt antiinflammatorisk lægemiddel (NSAID).
- 6. Coatet substrat ifølge krav 5, hvori det farmaceutisk aktive middel er et antibiotikum udvalgt fra doxycyclin og doxycyclinhyclat.
- 7. Coatet substrat ifølge krav 4, hvori det farmaceutisk aktive middel er et anticancermiddel; eller hvori det farmaceutisk aktive middel er et steroid.
- 8. Coatet substrat ifølge krav 5, hvori det farmaceutisk aktive middel er udvalgt fra en osteogen faktor eller en knogleresorptionshæmmer.
- 9. Coatet substrat ifølge et hvilket som helst af kravene 1 til 8 til vedvarende udløsning af det farmaceutisk aktive middel, hvori udløsningstiden for 90 % af det farmaceutisk aktive middel in vivo er mellem 1 uge og 6 måneder.
- 10. Coatet substrat ifølge et hvilket som helst af kravene 1 til 9, hvori substratet er en del af et implantat.
- 11. Coatet substrat ifølge krav 5 til behandling af periodontitis hos et subjekt eller ifølge krav 8 til stimulering af knogleforstærkning hos et subjekt.
- 12. Medicinsk anordning omfattende det coatede substrat ifølge et hvilket som helst af kravene 1 til 9.
- 13. Fremgangsmåde til fremstilling af et substrat coatet med en matrixsammensætning ifølge krav 1, hvilken fremgangsmåde omfatter trinnene med: a) at blande i et første flygtigt organisk opløsningsmiddel: (i) en biologisk nedbrydelig polyester og (ii) en første lipid omfattende en sterol; b) at blande i et andet flygtigt organisk opløsningsmiddel: (i) mindst ét farmaceutisk aktivt middel, (ii) en anden lipid omfattende mindst én phosphatidylcholin med fedtsyredele på mindst 14 carbonatomer; c) at blande produkterne, der er resultat af trin (a) og (b), så der dannes en homogen blanding: d) at bringe blandingen, der er resultat af trin c), i kontakt med et substrat og e) mens den er i kontakt med substratet at fordampe de flygtige organiske opløsningsmidler; hvori hvert trin i fremgangsmåden i det væsentlige er fri for en vandig opløsning, hvorved der dannes en homogen matrixsammensætning.
- 14. Fremgangsmåde ifølge krav 13, hvori fordampningen udføres ved en temperatur i området rumtemperatur til 60 grader Celsius.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8028908P | 2008-07-14 | 2008-07-14 | |
US15478509P | 2009-02-24 | 2009-02-24 | |
PCT/IL2009/000701 WO2010007623A1 (en) | 2008-07-14 | 2009-07-14 | Sustained-release drug carrier composition |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2299953T3 true DK2299953T3 (da) | 2017-06-19 |
Family
ID=41550058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK09797631.0T DK2299953T3 (da) | 2008-07-14 | 2009-07-14 | Bærestofsammensætning til lægemidler med vedvarende udløsning |
Country Status (11)
Country | Link |
---|---|
US (6) | US8877242B2 (da) |
EP (1) | EP2299953B1 (da) |
JP (3) | JP5681626B2 (da) |
CN (2) | CN104274866B (da) |
AU (1) | AU2009272280B2 (da) |
CA (1) | CA2730340C (da) |
DK (1) | DK2299953T3 (da) |
ES (1) | ES2630805T3 (da) |
HK (1) | HK1205960A1 (da) |
PL (1) | PL2299953T3 (da) |
WO (1) | WO2010007623A1 (da) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN2012DN00570A (da) | 2009-07-14 | 2015-06-12 | Polypid Ltd | |
WO2011089595A2 (en) | 2010-01-19 | 2011-07-28 | Polypid Ltd. | Sustained-release nucleic acid matrix compositions |
US9119793B1 (en) | 2011-06-28 | 2015-09-01 | Medicis Pharmaceutical Corporation | Gastroretentive dosage forms for doxycycline |
CA2838481A1 (en) * | 2011-07-27 | 2013-01-31 | Polypid Ltd. | Matrix compositions for controlled release of peptide and polypeptide molecules |
CN102362861B (zh) * | 2011-11-04 | 2014-03-26 | 无锡中科光远生物材料有限公司 | 一种空心核壳结构复合纳米粒子及其制备方法 |
US20130288951A1 (en) * | 2012-04-27 | 2013-10-31 | Biomet Manufacturing Corp. | Compositions and methods for coating implant surfaces to inhibit surgical infections |
US20150140109A1 (en) * | 2012-05-18 | 2015-05-21 | Unichempharm Ltd | Docetaxel-based prolonged-release cancer treatment drug |
SG11201500403RA (en) * | 2012-08-02 | 2015-02-27 | Polypid Ltd | Compositions and methods for the treatment of bone voids and open fractures |
US10842802B2 (en) | 2013-03-15 | 2020-11-24 | Medicis Pharmaceutical Corporation | Controlled release pharmaceutical dosage forms |
US20160317560A1 (en) * | 2013-11-07 | 2016-11-03 | The University Of North Carolina At Chapel Hill | Particles containing phospholipids or bioactive fatty acids and uses thereof |
US20160340659A1 (en) | 2014-01-30 | 2016-11-24 | Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd. | Actin binding peptides and compositions comprising same for inhibiting angiogenesis and treating medical conditions associated with same |
EP3160449B1 (en) | 2014-06-24 | 2023-12-13 | The Trustees of Princeton University | Process for encapsulating soluble biologics, therapeutics, and imaging agents |
WO2016020901A1 (en) | 2014-08-07 | 2016-02-11 | Acerta Pharma B.V. | Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate |
CN107072885B (zh) * | 2014-10-02 | 2021-08-17 | 波利皮得有限公司 | 用于治疗种植体周围炎的方法 |
KR20170063638A (ko) | 2014-10-02 | 2017-06-08 | 폴리피드 엘티디. | 수술 부위 감염의 치료 및 예방을 위한 조성물 및 방법 |
WO2016168718A1 (en) * | 2015-04-17 | 2016-10-20 | Massachusetts Eye And Ear Infirmary | Prosthetic devices for semicircular canal defects |
KR101773287B1 (ko) * | 2016-03-10 | 2017-08-31 | 고려대학교 산학협력단 | 골수염 치료 장치 |
CN107921179B (zh) | 2015-07-10 | 2020-12-22 | 高丽大学校产学协力团 | 医疗伤口愈合促进器和骨髓炎治疗装置 |
US11103461B2 (en) * | 2015-12-22 | 2021-08-31 | The Trustees Of Princeton University | Process for encapsulating soluble biologics, therapeutics, and imaging agents |
WO2018107243A1 (en) * | 2016-12-16 | 2018-06-21 | Field Orthopaedics Pty Ltd | A medical implant and a method of coating a medical implant |
WO2019055539A1 (en) | 2017-09-12 | 2019-03-21 | Prudhomme Robert K | CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME |
US11731099B2 (en) | 2018-07-20 | 2023-08-22 | The Trustees Of Princeton University | Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation |
JP7395210B2 (ja) * | 2019-08-08 | 2023-12-11 | アヴィデンス セラピューティクス, インコーポレイテッド | ミクロスフェアに基づく注射用セレコキシブ製剤 |
TWI754876B (zh) * | 2019-12-31 | 2022-02-11 | 財團法人工業技術研究院 | 含藥多層薄膜與其形成方法 |
AU2021405274A1 (en) | 2020-12-21 | 2023-06-08 | Polypid Ltd. | Compositions and methods for the treatment of solid tumors |
KR102442807B1 (ko) | 2021-01-29 | 2022-09-15 | 주식회사 티온랩테라퓨틱스 | 초기 방출 제어된 데포 조성물 및 이의 제조방법 |
US20220296524A1 (en) | 2021-01-29 | 2022-09-22 | Tionlab Therapeutics | Initial burst release controlled depot composition and a method thereof |
KR20230115591A (ko) | 2022-01-27 | 2023-08-03 | 주식회사 티온랩테라퓨틱스 | 초기 방출 제어된 지질 융합 데포 조성물 및 이의 제조방법 |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4522803A (en) | 1983-02-04 | 1985-06-11 | The Liposome Company, Inc. | Stable plurilamellar vesicles, their preparation and use |
US4882167A (en) | 1983-05-31 | 1989-11-21 | Jang Choong Gook | Dry direct compression compositions for controlled release dosage forms |
US4578384A (en) | 1984-02-15 | 1986-03-25 | The United States Of America As Represented By The Secretary Of The Army | Polylactic-polyglycolic acids combined with an acidic phospholipid-lysozyme complex for healing osseous tissue |
US4522863A (en) | 1984-06-21 | 1985-06-11 | Kimberly-Clark Corporation | Soft nonwoven laminate bonded by adhesive on reinforcing scrim |
JPS6163613A (ja) | 1984-09-04 | 1986-04-01 | Mitsui Toatsu Chem Inc | 顆粒状に調整された徐放性製剤 |
US5043166A (en) | 1987-01-09 | 1991-08-27 | Hadasit Medical Research, Inc. | Liposome/anthraquinone drug composition and method |
IL91664A (en) | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
EP0502119B1 (en) | 1989-11-13 | 1996-01-31 | Scios Nova, Inc. | Lipospheres for controlled delivery of substances |
US6120805A (en) | 1990-04-06 | 2000-09-19 | Rhone-Poulenc Rorer Sa | Microspheres, process for their preparation and their use |
JPH046115A (ja) | 1990-04-25 | 1992-01-10 | Olympus Optical Co Ltd | 光学素子成形用型 |
DK166600B1 (da) | 1991-01-17 | 1993-06-21 | Therkel Bisgaard | Vaerktoejssaet til brug ved suturering i dybe operationsaabninger eller legemshulrum |
US5922340A (en) | 1992-09-10 | 1999-07-13 | Children's Medical Center Corporation | High load formulations and methods for providing prolonged local anesthesia |
US6180134B1 (en) | 1993-03-23 | 2001-01-30 | Sequus Pharmaceuticals, Inc. | Enhanced ciruclation effector composition and method |
WO1995024929A2 (en) | 1994-03-15 | 1995-09-21 | Brown University Research Foundation | Polymeric gene delivery system |
US6156337A (en) | 1994-07-08 | 2000-12-05 | Opperbas Holding B.V. | Method for high loading of vesicles with biopolymeric substances |
US6333021B1 (en) | 1994-11-22 | 2001-12-25 | Bracco Research S.A. | Microcapsules, method of making and their use |
US6040295A (en) | 1995-01-13 | 2000-03-21 | Genemedicine, Inc. | Formulated nucleic acid compositions and methods of administering the same for gene therapy |
US5919480A (en) | 1996-06-24 | 1999-07-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Liposomal influenza vaccine composition and method |
JPH108035A (ja) | 1996-06-25 | 1998-01-13 | Akebono Brake Ind Co Ltd | 非石綿系摩擦材 |
US5837221A (en) | 1996-07-29 | 1998-11-17 | Acusphere, Inc. | Polymer-lipid microencapsulated gases for use as imaging agents |
AU3981097A (en) | 1996-08-21 | 1998-03-06 | Alkermes Controlled Therapeutics, Inc. | Controlled release microparticles with a hydrophobic material |
CA2263568C (en) | 1996-09-11 | 2008-12-02 | Imarx Pharmaceutical Corp. | Methods for diagnostic imaging using a contrast agent and a renal vasodilator |
US6048551A (en) | 1997-03-27 | 2000-04-11 | Hilfinger; John M. | Microsphere encapsulation of gene transfer vectors |
BR9815499A (pt) | 1997-07-02 | 2001-01-02 | Euro Celtique Sa | Anestesia prolongada nas juntas e nos espacos corporais. |
US6287587B2 (en) | 1997-07-15 | 2001-09-11 | Takeda Chemical Industries, Ltd. | Process for producing sustained-release preparation by in-water drying |
US6787132B1 (en) | 1997-12-04 | 2004-09-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Combined chemo-immunotherapy with liposomal drugs and cytokines |
PT1079805E (pt) | 1998-04-27 | 2005-03-31 | Opperbas Holding Bv | Composicao farmaceutica compreendendo factor viii e lipossomas neutros |
US6423345B2 (en) | 1998-04-30 | 2002-07-23 | Acusphere, Inc. | Matrices formed of polymer and hydrophobic compounds for use in drug delivery |
JP2002520120A (ja) * | 1998-07-17 | 2002-07-09 | スカイファーマ インコーポレーテッド | 封入物質の制御放出のための生分解性組成物 |
CA2340118C (en) | 1998-08-12 | 2009-01-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Liposomal bupivacaine compositions prepared using an ammonium sulfate gradient |
US6153217A (en) | 1999-01-22 | 2000-11-28 | Biodelivery Sciences, Inc. | Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents |
US6083482A (en) | 1999-05-11 | 2000-07-04 | Icn Pharmaceuticals, Inc. | Conformationally locked nucleosides and oligonucleotides |
WO2000078357A2 (en) | 1999-06-18 | 2000-12-28 | The Collaborative Group, Ltd. | Hyaluronic acid film and matrix for sustained gene transfer |
DE10001172A1 (de) | 2000-01-13 | 2001-07-26 | Max Planck Gesellschaft | Templatieren von Feststoffpartikeln mit Polymermultischichten |
US6267587B1 (en) * | 2000-07-06 | 2001-07-31 | Johnson & Johnson Vision Care, Inc. | Thermal curing oven and thermal curing process |
US6967028B2 (en) | 2000-07-31 | 2005-11-22 | Mainelab | Prolonged release microspheres for injectable administration |
WO2002028408A2 (en) | 2000-10-02 | 2002-04-11 | Arizeke Pharmaceuticals, Inc. | Compositions and methods for the transport of biologically active agents across cellular barriers |
US7749539B2 (en) * | 2000-11-30 | 2010-07-06 | Efrat Biopolymers Ltd. | Polymeric formulations for drug delivery |
FI20010540A0 (fi) * | 2001-03-16 | 2001-03-16 | Yli Urpo Antti | Komposiitti pehmyt- ja kovakudosvammojen korjaamiseksi ja mainitun komposiitin käyttö |
EP1429742B1 (en) | 2001-09-28 | 2011-05-04 | McNeil-PPC, Inc. | Modified release dosage forms |
TWI226249B (en) | 2001-12-19 | 2005-01-11 | Ind Tech Res Inst | Biodegradable composite matrix for enhancing angiogenesis |
AU2003215402A1 (en) * | 2002-02-22 | 2003-09-09 | Purdue Research Foundation | Fe/au nanoparticles and methods |
AU2003237864B2 (en) | 2002-05-15 | 2008-12-18 | California Pacific Medical Center | Delivery of nucleic acid-like compounds |
US7144430B2 (en) * | 2002-07-12 | 2006-12-05 | Motion Control, Inc. | Wrist device for use with a prosthetic limb |
SE0202619D0 (sv) * | 2002-09-05 | 2002-09-05 | Fredrik Nederberg | New Polymers and Applications |
US9107751B2 (en) * | 2002-12-12 | 2015-08-18 | Warsaw Orthopedic, Inc. | Injectable and moldable bone substitute materials |
ES2695401T3 (es) | 2003-02-12 | 2019-01-04 | Syncera Inc | Composiciones de aleación de polímeros de óxido de alquileno aleatorios y no aleatorios |
GB0305941D0 (en) | 2003-03-14 | 2003-04-23 | Camurus Ab | Composition |
CA2521916C (en) | 2003-04-10 | 2013-06-25 | Teijin Limited | Biodegradable film having a honeycomb structure for the prevention of postoperative tissue adhesion |
US20040247624A1 (en) * | 2003-06-05 | 2004-12-09 | Unger Evan Charles | Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility |
US20060188573A1 (en) | 2003-06-10 | 2006-08-24 | Anna Imberg | Composite materials and particles |
WO2005039489A2 (en) | 2003-09-24 | 2005-05-06 | Polymerix Corporation | Compositions and methods for the inhibition of bone growth and resorption |
JP2005154514A (ja) * | 2003-11-21 | 2005-06-16 | Univ Waseda | 機能性生分解性材料およびその製造方法 |
EP1693075B1 (en) | 2003-11-21 | 2012-10-03 | Teijin Limited | Substrate for tissue regeneration |
WO2005070466A2 (en) | 2004-01-15 | 2005-08-04 | Alza Corporation | Liposome composition for delivery of therapeutic agents |
US8277831B2 (en) | 2004-02-17 | 2012-10-02 | Advanced Technologies And Regenerative Medicine, Llc. | Drug-enhanced adhesion prevention |
US7744644B2 (en) | 2004-03-19 | 2010-06-29 | Boston Scientific Scimed, Inc. | Medical articles having regions with polyelectrolyte multilayer coatings for regulating drug release |
RU2390331C2 (ru) | 2004-06-04 | 2010-05-27 | Камурус Аб | Жидкие депо-препараты |
CA2612006A1 (en) * | 2004-06-15 | 2006-01-05 | Encore Therapeutics, Inc. | Phospholipid compositions and methods for their preparation and use |
WO2006009825A1 (en) | 2004-06-17 | 2006-01-26 | Virun, Inc. | Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents |
MX2007000979A (es) * | 2004-07-26 | 2007-07-11 | Cotherix Inc | Tratamiento de la hipertension pulmonar por iloprost inhalado con una formulacion microparticulada. |
JP4046115B2 (ja) | 2004-11-01 | 2008-02-13 | セイコーエプソン株式会社 | デバイスの製造方法、電気光学装置、電子機器 |
MX2007013213A (es) | 2005-04-25 | 2007-12-12 | Amgen Inc | Composiciones de liberacion prolongada de peptidos biodegradables que contienen porogenos. |
US20070141134A1 (en) | 2005-12-16 | 2007-06-21 | Kosak Matthew K | Shielded micelles for polynucleotide delivery |
US20090318355A1 (en) | 2006-02-15 | 2009-12-24 | Chen Thomas T | Compositions and methods for promoting tissue repair and wound healing |
JP2009534309A (ja) | 2006-03-31 | 2009-09-24 | マサチューセッツ インスティテュート オブ テクノロジー | 治療剤の標的化送達のためのシステム |
US8703167B2 (en) | 2006-06-05 | 2014-04-22 | Advanced Cardiovascular Systems, Inc. | Coatings for implantable medical devices for controlled release of a hydrophilic drug and a hydrophobic drug |
BRPI0807290A2 (pt) | 2007-03-02 | 2016-10-11 | Teika Pharmaceutical Co Ltd | "composição medicinal para absorção transdérmica, unidade de armazenamento de composição medicinal e prepraração de absorção transdérmica usando a mesma" |
WO2008124634A1 (en) | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Polymer-encapsulated reverse micelles |
US20090006311A1 (en) * | 2007-06-28 | 2009-01-01 | Yahoo! Inc. | Automated system to improve search engine optimization on web pages |
WO2009006311A2 (en) * | 2007-06-29 | 2009-01-08 | Wisconsin Alumni Research Foundation | Structuring effect of cholesterol in peg-phospholipid micelles, drug delivery of amphotericin b, and combination antifungals |
US20090110713A1 (en) | 2007-10-31 | 2009-04-30 | Florencia Lim | Biodegradable polymeric materials providing controlled release of hydrophobic drugs from implantable devices |
MX2010005089A (es) | 2007-11-09 | 2010-05-21 | Univ Northeastern | Nanoparticulas tipo micela autoensambles para el suministro sistemico de genes. |
WO2009110939A2 (en) | 2007-12-10 | 2009-09-11 | Massachusetts Institute Of Technology | Drug delivery system for pharmaceuticals and radiation |
TWI373474B (en) | 2007-12-31 | 2012-10-01 | Univ Kaohsiung Medical | Stem cell transfection method |
US8685432B2 (en) * | 2008-03-25 | 2014-04-01 | University Of Utah Research Foundation | Controlled release tissue graft combination biomaterials |
US8128983B2 (en) | 2008-04-11 | 2012-03-06 | Abbott Cardiovascular Systems Inc. | Coating comprising poly(ethylene glycol)-poly(lactide-glycolide-caprolactone) interpenetrating network |
PL2279254T3 (pl) | 2008-04-15 | 2017-11-30 | Protiva Biotherapeutics Inc. | Nowe preparaty lipidowe do dostarczania kwasów nukleinowych |
IN2012DN00570A (da) | 2009-07-14 | 2015-06-12 | Polypid Ltd | |
KR101114771B1 (ko) | 2009-09-23 | 2012-03-05 | 유영환 | 석쇠 |
WO2011089595A2 (en) | 2010-01-19 | 2011-07-28 | Polypid Ltd. | Sustained-release nucleic acid matrix compositions |
-
2009
- 2009-07-14 DK DK09797631.0T patent/DK2299953T3/da active
- 2009-07-14 ES ES09797631.0T patent/ES2630805T3/es active Active
- 2009-07-14 WO PCT/IL2009/000701 patent/WO2010007623A1/en active Application Filing
- 2009-07-14 CA CA2730340A patent/CA2730340C/en active Active
- 2009-07-14 AU AU2009272280A patent/AU2009272280B2/en active Active
- 2009-07-14 US US13/003,955 patent/US8877242B2/en active Active
- 2009-07-14 EP EP09797631.0A patent/EP2299953B1/en active Active
- 2009-07-14 CN CN201410412237.0A patent/CN104274866B/zh active Active
- 2009-07-14 PL PL09797631T patent/PL2299953T3/pl unknown
- 2009-07-14 CN CN200980133937.3A patent/CN102159163B/zh active Active
- 2009-07-14 JP JP2011518059A patent/JP5681626B2/ja active Active
-
2014
- 2014-10-26 US US14/523,893 patent/US20150071981A1/en not_active Abandoned
- 2014-10-26 US US14/523,894 patent/US9421271B2/en active Active
-
2015
- 2015-01-08 JP JP2015002177A patent/JP2015129128A/ja not_active Ceased
- 2015-07-13 HK HK15106684.1A patent/HK1205960A1/xx unknown
-
2016
- 2016-02-10 JP JP2016023906A patent/JP6053083B2/ja active Active
- 2016-08-23 US US15/244,048 patent/US10105443B2/en active Active
-
2018
- 2018-09-06 US US16/122,986 patent/US10682412B2/en active Active
-
2020
- 2020-06-02 US US16/889,826 patent/US20200289651A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2009272280A1 (en) | 2010-01-21 |
WO2010007623A1 (en) | 2010-01-21 |
US20150071981A1 (en) | 2015-03-12 |
CN102159163B (zh) | 2014-09-10 |
US9421271B2 (en) | 2016-08-23 |
ES2630805T3 (es) | 2017-08-24 |
JP2011528031A (ja) | 2011-11-10 |
CN104274866A (zh) | 2015-01-14 |
EP2299953A1 (en) | 2011-03-30 |
CN102159163A (zh) | 2011-08-17 |
US20150050340A1 (en) | 2015-02-19 |
JP6053083B2 (ja) | 2016-12-27 |
CN104274866B (zh) | 2016-08-24 |
US20190070298A1 (en) | 2019-03-07 |
HK1205960A1 (en) | 2015-12-31 |
EP2299953A4 (en) | 2013-05-29 |
US20110117197A1 (en) | 2011-05-19 |
JP2016145217A (ja) | 2016-08-12 |
CA2730340A1 (en) | 2010-01-21 |
AU2009272280B2 (en) | 2015-08-06 |
US8877242B2 (en) | 2014-11-04 |
EP2299953B1 (en) | 2017-04-12 |
US10105443B2 (en) | 2018-10-23 |
JP5681626B2 (ja) | 2015-03-11 |
US20160354470A1 (en) | 2016-12-08 |
US10682412B2 (en) | 2020-06-16 |
CA2730340C (en) | 2017-02-07 |
JP2015129128A (ja) | 2015-07-16 |
US20200289651A1 (en) | 2020-09-17 |
PL2299953T3 (pl) | 2017-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10682412B2 (en) | Sustained-release drug carrier composition | |
US10463617B2 (en) | Sustained-release drug carrier composition | |
US10758639B2 (en) | Methods for the treatment of peri-implantitis | |
IL210437A (en) | The drug carries a drug for sustained release |